ICU Medical (NASDAQ:ICUI) Updates FY 2026 Earnings Guidance

ICU Medical (NASDAQ:ICUI) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 8.600-9.000 for the period, compared to the consensus estimate of 7.830. The company issued revenue guidance of -.

ICU Medical Trading Down 0.0%

ICU Medical stock traded down $0.03 during mid-day trading on Thursday, hitting $166.37. The stock had a trading volume of 359,613 shares, compared to its average volume of 299,228. The stock has a 50-day simple moving average of $150.66 and a two-hundred day simple moving average of $140.72. The stock has a market capitalization of $4.16 billion, a PE ratio of 89.93, a P/E/G ratio of 2.32 and a beta of 0.74. ICU Medical has a 12 month low of $107.00 and a 12 month high of $176.27. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The company had revenue of $547.88 million during the quarter, compared to analysts’ expectations of $533.44 million. During the same quarter in the previous year, the company posted $2.10 EPS. The business’s revenue for the quarter was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, sell-side analysts forecast that ICU Medical will post 6.51 EPS for the current year.

Wall Street Analyst Weigh In

ICUI has been the topic of several research analyst reports. KeyCorp upped their price objective on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research note on Tuesday, July 21st. Piper Sandler reduced their target price on ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Needham & Company LLC raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research report on Wednesday, May 27th. Weiss Ratings upgraded shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Finally, Jefferies Financial Group raised shares of ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $172.00.

Insider Buying and Selling at ICU Medical

In other news, Director David C. Greenberg sold 2,424 shares of the stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the sale, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. The trade was a 11.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ICU Medical

A number of institutional investors and hedge funds have recently bought and sold shares of ICUI. Cibc World Markets Corp bought a new position in ICU Medical in the fourth quarter worth approximately $228,000. CIBC Asset Management Inc bought a new stake in ICU Medical during the 4th quarter valued at $225,000. CIBC Bancorp USA Inc. bought a new stake in ICU Medical during the 3rd quarter valued at $309,000. Mercer Global Advisors Inc. ADV bought a new stake in ICU Medical during the 3rd quarter valued at $304,000. Finally, Lido Advisors LLC increased its holdings in shares of ICU Medical by 7.9% in the 3rd quarter. Lido Advisors LLC now owns 2,373 shares of the medical instruments supplier’s stock valued at $285,000 after acquiring an additional 174 shares during the period. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.